Tolcapone Side Effects
Some side effects of tolcapone may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to tolcapone: oral tablet
Get emergency medical help if you have any of these signs of an allergic reaction while taking tolcapone: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:
nausea, stomach pain, low fever, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
feeling like you might pass out;
fever, stiff muscles, confusion, and sweating (especially when you first start taking tolcapone);
tremors (uncontrolled shaking);
tight feeling in your chest, trouble breathing;
pain or burning when you urinate;
severe or ongoing diarrhea; or
muscle pain, tenderness, or weakness with fever or flu symptoms and dark colored urine.
Less serious side effects of tolcapone may include:
diarrhea or constipation;
headache, tired feeling;
unusual skin changes;
cold symptoms such as stuffy nose, sneezing, sore throat;
sleep problems (insomnia), dreaming more than usual; or
agitation or anxiety.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to tolcapone: oral tablet
In general, tolcapone was well tolerated in clinical trials with most adverse events being mild to moderate in severity. Dyskinesia and other dopaminergic-related effects were the most frequently reported adverse events in patients with motor fluctuations. Diarrhea was the most common nondopaminergic adverse event, occurring in up to 26% of patients who received tolcapone, and necessitating discontinuation of treatment in approximately 5% to 10% of patients.
Hepatic side effects have included severe liver damage, including fulminant liver failure resulting in death. Three cases of fatal fulminant hepatic failure have been reported from more than 40,000 patient years of worldwide use. Increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST) have also been reported.
Gastrointestinal side effects have included nausea (30% to 35%), anorexia (19% to 23%), diarrhea (16% to 18%), vomiting (8% to 10%), constipation (6% to 8%), xerostomia (5% to 6%), abdominal pain (5% to 6%), dyspepsia (3% to 4%), flatulence (2% to 4%), and dry mouth.
Musculoskeletal side effects have included dystonia (19% to 22%), muscle cramps (17% to 18%), stiffness (2%), arthritis (1% to 2%), and hypertonia (1%).
Respiratory side effects have included upper respiratory tract infection (5% to 7%), dyspnea (3%), and sinus congestion (1% to 2%).
Genitourinary side effects have included urine discoloration (2% to 7%), urinary tract infection (5%), and micturition disorder (1% to 2%).
Cardiovascular side effects have included chest pain (1% to 3%), hypotension (2%), chest discomfort (1% to 2%), and orthostatic symptoms.
A case report of vitiligo has been reported in a 50-year-old man with Parkinson's disease one week after the start of therapy with tolcapone 300 mg per day.
Dermatologic side effects have included dermal bleeding (1%), alopecia (1%), and increased sweating. At least one case of vitiligo has also been reported.
Oncologic side effects have included tumors of the skin (1%) and tumors of the uterus (1%).
Ocular side effects have included cataracts (1%) and inflamed eyes (1%).
Nervous system side effects have included dyskinesia (42% to 51%), sleep disorder (24% to 25%), excessive dreaming (16% to 21%), somnolence (14% to 18%), orthostatic complaints (17%), dizziness (6% to 13%), confusion (10% to 11%), headache (10% to 11%), hallucination (8% to 10%), syncope (4% to 5%), hyperkinesia (2% to 3%), paresthesia (1% to 3%), hypokinesia (1% to 3%), loss of balance (2% to 3%), mental deficiency (1%), agitation (1%), hyperactivity (1%), and neuroleptic malignant-like syndrome. Akathisia, insomnia and sleep disturbances have also been reported.
The neuroleptic malignant-like syndrome was reported in an elderly patient. It was caused by abrupt withdrawal of tolcapone.
Other side effects have included fatigue (3% to 7%), falling (4% to 6%), increased sweating (4% to 7%), influenza (3% to 4%), neck pain (2%), burning (1% to 2%), irritability (1%), malaise (1%), panic reaction (1%), euphoria (1%), and fever (1%).
More tolcapone resources
- tolcapone Concise Consumer Information (Cerner Multum)
- tolcapone MedFacts Consumer Leaflet (Wolters Kluwer)
- tolcapone Advanced Consumer (Micromedex) - Includes Dosage Information
- Tolcapone Professional Patient Advice (Wolters Kluwer)
- Tolcapone Monograph (AHFS DI)
- Tasmar Prescribing Information (FDA)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.